Search research articles
Contact Us
Filters
Showing results (91-100 of 114) with videos related to
Page
of 12
Sort By:
Journal of Opioid Management
|
July 26, 2019
Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management
Tony O'Brien, Jin Seok Ahn, Richard Chye, et al.
The Oncologist
|
April 10, 2020
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
Zhong-Zhe Lin, Bang-Bin Chen, Yi-Ping Hung, et al.
Frontiers in Medicine
|
November 25, 2022
Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma
Jan-Mou Lee, Yi-Ping Hung, Kai-Yuan Chou, et al.
Plos One
|
November 19, 2013
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
Zhong-Zhe Lin, Wen-Yi Shau, Chiun Hsu, et al.
Oncology
|
July 11, 2013
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study
Chih-Hung Hsu, Yoon Koo Kang, Tsai-Shen Yang, et al.
Cancers
|
October 23, 2021
Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy
Ying-Chun Shen, Ching-Ping Yeh, Yung-Ming Jeng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 24, 2022
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
Yu-Yun Shao, Yin-Hsun Feng, Chia-Jui Yen, et al.
Liver Cancer
|
August 8, 2024
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, et al.
Journal of Hepatocellular Carcinoma
|
June 10, 2024
Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma
Bang-Bin Chen, Po-Chin Liang, Tiffany Ting-Fang Shih, et al.
Oncology
|
July 12, 2014
β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
Li-Chun Lu, Yu-Yun Shao, Yi-Hsuan Lee, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 114) with videos related to
Sort By:
Page
of 12
Journal of Opioid Management
|
July 26, 2019
Understanding transdermal buprenorphine and a practical guide to its use for chronic cancer and non-cancer pain management
Tony O'Brien, Jin Seok Ahn, Richard Chye, et al.
The Oncologist
|
April 10, 2020
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
Zhong-Zhe Lin, Bang-Bin Chen, Yi-Ping Hung, et al.
Frontiers in Medicine
|
November 25, 2022
Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma
Jan-Mou Lee, Yi-Ping Hung, Kai-Yuan Chou, et al.
Plos One
|
November 19, 2013
Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size
Zhong-Zhe Lin, Wen-Yi Shau, Chiun Hsu, et al.
Oncology
|
July 11, 2013
Bevacizumab with erlotinib as first-line therapy in Asian patients with advanced hepatocellular carcinoma: a multicenter phase II study
Chih-Hung Hsu, Yoon Koo Kang, Tsai-Shen Yang, et al.
Cancers
|
October 23, 2021
Limited Predictive or Prognostic Role of Tumor-Infiltrating Tissue-Resident Memory CD8 T Cells in Patients with Hepatocellular Carcinoma Receiving Immunotherapy
Ying-Chun Shen, Ching-Ping Yeh, Yung-Ming Jeng, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi
|
September 24, 2022
Bevacizumab and atezolizumab as first-line therapy for advanced hepatocellular carcinoma: A Taiwanese subgroup analysis on efficacy and safety
Yu-Yun Shao, Yin-Hsun Feng, Chia-Jui Yen, et al.
Liver Cancer
|
August 8, 2024
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Masatoshi Kudo, Kaoru Tsuchiya, Yu-Yun Shao, et al.
Journal of Hepatocellular Carcinoma
|
June 10, 2024
Changes in Posttreatment Spleen Volume Associated with Immunotherapy Outcomes for Advanced Hepatocellular Carcinoma
Bang-Bin Chen, Po-Chin Liang, Tiffany Ting-Fang Shih, et al.
Oncology
|
July 12, 2014
β-catenin (CTNNB1) mutations are not associated with prognosis in advanced hepatocellular carcinoma
Li-Chun Lu, Yu-Yun Shao, Yi-Hsuan Lee, et al.
Page
of 12